These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

461 related items for PubMed ID: 8402644

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. PIK3CA mutation and histological type in breast carcinoma: high frequency of mutations in lobular carcinoma.
    Buttitta F, Felicioni L, Barassi F, Martella C, Paolizzi D, Fresu G, Salvatore S, Cuccurullo F, Mezzetti A, Campani D, Marchetti A.
    J Pathol; 2006 Feb; 208(3):350-5. PubMed ID: 16353168
    [Abstract] [Full Text] [Related]

  • 3. p53 mutations are confined to the comedo type ductal carcinoma in situ of the breast. Immunohistochemical and sequencing data.
    O'Malley FP, Vnencak-Jones CL, Dupont WD, Parl F, Manning S, Page DL.
    Lab Invest; 1994 Jul; 71(1):67-72. PubMed ID: 8041120
    [Abstract] [Full Text] [Related]

  • 4. p53 Gene alterations and p53 protein accumulation in infiltrating ductal breast carcinomas: correlation between immunohistochemical and molecular biology techniques.
    Hurlimann J, Chaubert P, Benhattar J.
    Mod Pathol; 1994 May; 7(4):423-8. PubMed ID: 8066070
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. p53, Ki-ras, and DNA ploidy in human pancreatic ductal adenocarcinomas.
    Weyrer K, Feichtinger H, Haun M, Weiss G, Ofner D, Weger AR, Umlauft F, Grünewald K.
    Lab Invest; 1996 Jan; 74(1):279-89. PubMed ID: 8569192
    [Abstract] [Full Text] [Related]

  • 7. Expression and amplification of cyclin D1 in primary breast carcinomas: relationship with histopathological types and clinico-pathological parameters.
    Naidu R, Wahab NA, Yadav MM, Kutty MK.
    Oncol Rep; 2002 Jan; 9(2):409-16. PubMed ID: 11836618
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. The association of p53 immunopositivity with tumor proliferation and other prognostic indicators in breast cancer.
    Bhargava V, Thor A, Deng G, Ljung BM, Moore DH, Waldman F, Benz C, Goodson W, Mayall B, Chew K.
    Mod Pathol; 1994 Apr; 7(3):361-8. PubMed ID: 8058709
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Carcinoma in situ of the female breast. A clinico-pathological, immunohistological, and DNA ploidy study.
    Ottesen GL.
    APMIS Suppl; 2003 Apr; (108):1-67. PubMed ID: 12874968
    [Abstract] [Full Text] [Related]

  • 12. The timing and characterization of p53 mutations in progression from atypical ductal hyperplasia to invasive lesions in the breast cancer.
    Kang JH, Kim SJ, Noh DY, Choe KJ, Lee ES, Kang HS.
    J Mol Med (Berl); 2001 Nov; 79(11):648-55. PubMed ID: 11715068
    [Abstract] [Full Text] [Related]

  • 13. Loss of heterozygosity and p53 gene mutations in breast cancer.
    Deng G, Chen LC, Schott DR, Thor A, Bhargava V, Ljung BM, Chew K, Smith HS.
    Cancer Res; 1994 Jan 15; 54(2):499-505. PubMed ID: 8275488
    [Abstract] [Full Text] [Related]

  • 14. Expression of full-length p53 and its isoform Deltap53 in breast carcinomas in relation to mutation status and clinical parameters.
    Baumbusch LO, Myhre S, Langerød A, Bergamaschi A, Geisler SB, Lønning PE, Deppert W, Dornreiter I, Børresen-Dale AL.
    Mol Cancer; 2006 Oct 20; 5():47. PubMed ID: 17054774
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Abnormal expression of cell cycle regulatory proteins in ductal and lobular carcinomas of the breast.
    Geradts J, Ingram CD.
    Mod Pathol; 2000 Sep 20; 13(9):945-53. PubMed ID: 11007034
    [Abstract] [Full Text] [Related]

  • 18. Correlations among p53, Her-2/neu, and ras overexpression and aneuploidy by multiparameter flow cytometry in human breast cancer: evidence for a common phenotypic evolutionary pattern in infiltrating ductal carcinomas.
    Smith CA, Pollice AA, Gu LP, Brown KA, Singh SG, Janocko LE, Johnson R, Julian T, Hyams D, Wolmark N, Sweeney L, Silverman JF, Shackney SE.
    Clin Cancer Res; 2000 Jan 20; 6(1):112-26. PubMed ID: 10656439
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Interest of investigating p53 status in breast cancer by four different methods.
    Thirion A, Rouanet P, Thezenas S, Detournay D, Grenier J, Lopez-Crapez E.
    Oncol Rep; 2002 Jan 20; 9(6):1167-72. PubMed ID: 12375013
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.